TOKYO, June 1 (Reuters) - Japan's Shionogi & Co said on Monday the U.S. Food and Drug Administration has approved its oral ...

The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to ...

After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the ...

Many people are still suffering from the aftereffects of COVID-19, such as coughing, breathing difficulties and fatigue, four ...

Japan on March 1 lifted its COVID-19-related entry ban on foreign travelers and raised the maximum daily number of entrants from 3,500 to 5,000.

The FDA approved the oral antiviral agent ensitrelvir (Xocova) to help prevent COVID-19 in people ages 12 years or older who were exposed to the SARS-CoV-2 virus, drugmaker Shionogi announced.

Japanese version The data on this "Coronavirus (COVID-19) infections in Japan" page is based on original coverage by the Mainichi Shimbun and press releases from the Ministry of Health, Labor and ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Tokyo — As Tokyo and the surrounding area chart frightening new levels of COVID-19 infection, Japanese Prime Minister Yoshihide Suga has declared a state of emergency in the region for the second time ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. People wait to ...